Biomedicine & Pharmacotherapy,
Год журнала:
2024,
Номер
177, С. 116925 - 116925
Опубликована: Июнь 15, 2024
Macrophages
are
central
to
the
immune
system
and
found
in
nearly
all
tissues.
Recently,
development
of
therapies
based
on
macrophages
has
attracted
significant
interest.
These
utilize
macrophages'
key
roles
immunity,
their
ability
navigate
biological
barriers,
tendency
accumulate
tumors.
This
review
explores
advancement
macrophage-based
treatments.
We
discuss
bioengineering
for
improved
anti-tumor
effects,
use
CAR
macrophage
therapy
targeting
cancer
cells,
as
vehicles
therapeutic
delivery.
Additionally,
we
examine
engineered
products,
like
extracellular
vesicles
membrane-coated
nanoparticles,
potential
precise
less
toxic
tumor
therapy.
Challenges
moving
these
from
research
clinical
practice
also
highlighted.
The
aim
is
succinctly
summarize
current
status,
challenges,
future
directions
Human Vaccines & Immunotherapeutics,
Год журнала:
2024,
Номер
20(1)
Опубликована: Янв. 28, 2024
The
research
and
development
of
messenger
RNA
(mRNA)
cancer
vaccines
have
gradually
overcome
numerous
challenges
through
the
application
personalized
antigens,
structural
optimization
mRNA,
alternative
RNA-based
vectors
efficient
targeted
delivery
vectors.
Clinical
trials
are
currently
underway
for
various
that
encode
tumor-associated
antigens
(TAAs),
tumor-specific
(TSAs),
or
immunomodulators.
In
this
paper,
we
summarize
mRNA
emergence
expression
in
vaccines.
We
begin
by
reviewing
advancement
utilization
state-of-the-art
lipid
nanoparticles
(LNPs),
followed
presenting
primary
classifications
clinical
applications
Collectively,
emerging
as
a
central
focus
immunotherapy,
offering
potential
to
address
multiple
treatment,
either
standalone
therapies
combination
with
current
treatments.
Abstract
Significant
advancements
have
been
made
in
the
application
of
chimeric
antigen
receptor
(CAR)-T
treatment
for
blood
cancers
during
previous
ten
years.
However,
its
effectiveness
treating
solid
tumors
is
still
lacking,
necessitating
exploration
alternative
immunotherapies
that
can
overcome
significant
challenges
faced
by
current
CAR-T
cells.
CAR-based
immunotherapy
against
shows
promise
with
emergence
macrophages,
which
possess
robust
phagocytic
abilities,
antigen-presenting
functions,
and
ability
to
modify
tumor
microenvironment
stimulate
adaptive
responses.
This
paper
presents
a
thorough
examination
latest
progress
CAR-M
therapy,
covering
both
basic
scientific
studies
clinical
trials.
study
examines
primary
obstacles
hindering
realization
complete
potential
as
well
strategies
be
employed
these
hurdles.
With
revolutionary
technologies
like
situ
genetic
modification,
synthetic
biology
techniques,
biomaterial-supported
gene
transfer,
provide
wider
array
resources
manipulating
tumor-associated
we
suggest
combining
advanced
methods
will
result
creation
new
era
therapy
demonstrates
improved
efficacy,
safety,
availability.
Graphical
Biomarker Research,
Год журнала:
2024,
Номер
12(1)
Опубликована: Авг. 23, 2024
Abstract
With
the
advent
of
adoptive
cellular
therapy,
chimeric
antigen
receptor
(CAR)-T
cell
therapy
has
gained
widespread
application
in
cancer
treatment
and
demonstrated
significant
efficacy
against
certain
hematologic
malignancies.
However,
due
to
limitations
CAR-T
treating
solid
tumors,
other
immune
cells
are
being
modified
with
CAR
address
this
issue.
Macrophages
have
emerged
as
a
promising
option,
owing
their
extensive
functions,
which
include
presentation,
powerful
tumor
phagocytosis,
particularly
active
trafficking
microenvironment.
Leveraging
unique
advantages,
CAR-macrophages
(CAR-M)
expected
enhance
effectiveness
treatments
novel
form
immunotherapy,
potentially
overcoming
major
challenges
associated
CAR-T/NK
therapy.
This
review
outlines
primary
mechanism
underlying
CAR-M
recent
progressions
while
also
discussing
further
applications.
Advanced Materials,
Год журнала:
2024,
Номер
36(15)
Опубликована: Янв. 17, 2024
In
the
past
decade,
adoptive
cell
therapy
with
chimeric
antigen
receptor-T
(CAR-T)
cells
has
revolutionized
cancer
treatment.
However,
complexity
and
high
costs
involved
in
manufacturing
current
greatly
inhibit
its
widespread
availability
access.
To
address
this,
situ
therapy,
which
directly
reprograms
immune
inside
body,
recently
been
developed
as
a
promising
alternative.
Here,
an
overview
of
recent
progress
development
synthetic
nanomaterials
is
provided
to
deliver
plasmid
DNA
or
mRNA
for
reprogramming
T
macrophages,
focusing
especially
on
CAR
therapies.
Also,
main
challenges
are
discussed
some
approaches
overcome
these
barriers
fulfill
clinical
applications
proposed.
Journal of Advanced Research,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
After
significant
advancements
in
tumor
treatment,
personalized
cell
therapy
based
on
chimeric
antigen
receptors
(CAR)
holds
promise
for
transforming
the
management
of
various
diseases.
CAR-T
therapy,
first
approved
CAR
product,
has
demonstrated
therapeutic
potential
treating
infectious
diseases,
autoimmune
disorders,
and
fibrosis.
CAR-macrophages
(CAR-Ms)
are
emerging
as
a
promising
approach
immune
particularly
solid
highlighting
feasibility
using
macrophages
to
eliminate
pathogens
abnormal
cells.
Research Square (Research Square),
Год журнала:
2025,
Номер
unknown
Опубликована: Март 7, 2025
Abstract
Therapeutic
strategies
for
peritoneal
metastasis
in
solid
tumors
are
urgently
needed
the
clinic.
Programming
chimeric
antigen
receptor
macrophages
(CAR-Ms)
in
situ
offers
opportunities
an
unmet
demand.
However,
potential
intracellular
domains
(ICDs)
CAR
design
and
their
antitumor
mechanisms
macrophage
empowerment
remain
to
be
explored
systematically.
By
developing
a
targeted
mRNA-LNP
delivery
system
macrophages,
we
have
investigated
36
combinations
determine
impact
of
CAR-Ms
on
immune
regulation
vitro
vivo.
In
two
tumor
mouse
models,
intraperitoneal
programming
was
shown
elicit
robust
adaptive
activation
significantly
synergize
with
PD-1/L1
therapy.
Single-cell
RNA
sequencing
(scRNA-seq)
analysis
revealed
that
could
reshape
immunosuppressive
microenvironment
(TME)
boost
TCF1+PD-1+
progenitor-exhausted
CD8+
T
cells
(Tpex)
population.
Meanwhile,
found
tailored
CAR-M
CD3ζ/TLR4
ICDs
favorably
maintain
proinflammatory
phenotype
simultaneously
upregulate
MHC
I
PD-L1
expression
by
perturbing
NF-κB
pathways.
Moreover,
synergism
between
knockdown
therapy
highlighted
need
block
axis
cross-presentation.
short,
developed
vivo
broadened
understanding
both
regulatory
feedback
therapies
against
tumors.
Journal of Materials Chemistry B,
Год журнала:
2024,
Номер
12(20), С. 4759 - 4784
Опубликована: Янв. 1, 2024
This
paper
provides
a
comprehensive
review
of
the
structure,
composition,
and
applications
LNPs
in
treatment
hepatic
disorders
offers
insights
into
prospects
challenges
future
development
LNPs.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Ноя. 28, 2023
Macrophages
and
neutrophils
are
the
main
components
of
innate
immune
system
play
important
roles
in
promoting
angiogenesis,
extracellular
matrix
remodeling,
cancer
cell
proliferation,
metastasis
tumor
microenvironment
(TME).
They
can
also
be
harnessed
to
mediate
cytotoxic
killing
effects
orchestrate
effective
anti-tumor
responses
with
proper
stimulation
modification.
Therefore,
macrophages
have
strong
potential
immunotherapy.
In
this
review,
we
briefly
outlined
applications
or
adoptive
therapies,
focused
on
chimeric
antigen
receptor
(CAR)-engineered
(CAR-Ms)
(CAR-Ns).
We
summarized
construction
strategies,
preclinical
clinical
studies
CAR-Ms
CAR-Ns.
end,
discussed
limitations
challenges
CAR-Ns,
as
well
future
research
directions
extend
their
treating
solid
tumors.
